Preclinical Evaluation of the Acute Radiotoxicity of the α-Emitting Molecular-Targeted Therapeutic Agent 211At-MABG for the Treatment of Malignant Pheochromocytoma in Normal Mice.
Preclinical Evaluation of the Acute Radiotoxicity of the α-Emitting Molecular-Targeted Therapeutic Agent 211At-MABG for the Treatment of Malignant Pheochromocytoma in Normal Mice.
Transl Oncol. 2019 May 08;12(7):879-888
Authors: Sudo H, Tsuji AB, Sugyo A, Nagatsu K, Minegishi K, Ishioka NS, Ito H, Yoshinaga K, Higashi T
Abstract
The α-emitter 211At-labeled meta-astatobenzylguanidine (211At-MABG) has a strong antitumor effect on pheochromocytoma xenograft tumors and holds great promise as a new therapeutic option for malignant pheochromocytoma. To evaluate the acute radiation-related toxicity of 211At-MABG, we conducted biodistribution and dosimetry studies of 211At-MABG in ICR mice to estimate the doses absorbed by organs. We determined the maximum tolerated doses (MTD) of 211At-MABG on the basis of body weight loss and assessed the acute radiation-related toxicity induced by MTD administration on the basis of organ weights, histologic features, hematologic indices, and biochemical indices. The biodistribution and dosimetry studies of α-emitting 211At-MABG revealed high doses absorbed by most organs except the brain in ICR mice. The administration of 1.1, 2.2, and 3.3 MBq of 211At-MABG induced transient body weight loss, and 4.4 MBq of 211At-MABG induced unrecoverable body weight loss; thus, the MTD was 3.3 MBq for ICR mice. Although by day 5 the administration of 3.3 MBq had induced some radiation-related toxicity symptom...
Source: Translational Oncology - Category: Cancer & Oncology Authors: Sudo H, Tsuji AB, Sugyo A, Nagatsu K, Minegishi K, Ishioka NS, Ito H, Yoshinaga K, Higashi T Tags: Transl Oncol Source Type: research
More News: Brain | Brain Cancers | Cancer & Oncology | Cardiology | Heart | Hematology | Neurology | Pheochromocytoma | Radiation Therapy | Study | Thyroid | Toxicology | Weight Loss